Another study that utilised CRISPRi screening showed that BRD2 inhibition downregulates angiotensin converting enzyme 2 (ACE2) expression and controls the hyperactive immune response in COVID‐19 patients by downregulating interferon‐stimulated genes (ISGs).6 This evidence concerns the gene ACE2 and COVID-19.